Atkins Considers Comorbidities That Limit Use of IO Doublet in Advanced Melanoma
Source: Targeted Oncology, May 2024
PARTICIPANT LIST Raymond Lobins, DO | David Potter, MD | Mark Karwal, MD | Shahid Waheed, MD | Somasekhara R. Bandi, MD | Christiane Zoghbi, MD | Hilary Ufearo, MBBS
DISCUSSION QUESTIONS
Beyond the absence of an actionable BRAF mutation, what factors influence first-line selection of immunotherapy (IO) monotherapy vs dual IO therapy?
ATKINS: Can the person who [chose] pembrolizumab [Keytruda] tell me why you chose that?
